Jemma Arakelyan, Chief Executive Officer at The Institute of Cancer and Crisis (ICC) and Medical Advisor at Immune Oncology Research Institute, shared a post on LinkedIn:
“Our team’s latest work on novel nitric oxide-donating prodrugs for malignant pleural mesothelioma is now out in Pharmaceutics MDPI.”
Title: Bis-Oxadiazole Assemblies as NO-Releasing Anticancer Agents
Authors: Egor M. Matnurov, Irina A. Stebletsova, Alexander A. Larin, Jemma Arakelyan, Ivan V. Ananyev, Artem L. Gushchin, Leonid L. Fershtat, Maria V. Babak
More posts featuring Jemma Arakelyan on OncoDaily.